Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,250 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.
Dang NH, Ogura M, Castaigne S, Fayad LE, Jerkeman M, Radford J, Pezzutto A, Bondarenko I, Stewart DA, Shnaidman M, Sullivan S, Vandendries E, Tobinai K, Ramchandren R, Hamlin PA, Giné E, Ando K. Dang NH, et al. Among authors: ogura m. Br J Haematol. 2018 Aug;182(4):583-586. doi: 10.1111/bjh.14820. Epub 2017 Jul 5. Br J Haematol. 2018. PMID: 28677896 Free PMC article. Clinical Trial. No abstract available.
A dose-finding study of glycosylated G-CSF (Lenograstim) combined with CHOP therapy for stem cell mobilization in patients with non-Hodgkin's lymphoma.
Takeyama K, Ogura M, Morishima Y, Kasai M, Kiyama Y, Ohnishi K, Mitsuya H, Kawano F, Masaki Y, Sasaki T, Chou T, Yokozawa T, Tobinai K; Lenograstim/Lymphoma Study Group. Takeyama K, et al. Among authors: ogura m. Jpn J Clin Oncol. 2003 Feb;33(2):78-85. doi: 10.1093/jjco/hyg013. Jpn J Clin Oncol. 2003. PMID: 12629058 Clinical Trial.
Durable response but prolonged cytopenia after cladribine treatment in relapsed patients with indolent non-Hodgkin's lymphomas: results of a Japanese phase II study.
Ogura M, Morishima Y, Kobayashi Y, Uike N, Sugai S, Chou T, Kasai M, Miura I, Murayama T, Matsuno Y, Nakamura S, Mori S, Ohashi Y, Tobinai K; Cladribine Study Group. Ogura M, et al. Int J Hematol. 2004 Oct;80(3):267-77. doi: 10.1532/ijh97.04077. Int J Hematol. 2004. PMID: 15540903 Clinical Trial.
A randomized controlled trial investigating the survival benefit of dose-intensified multidrug combination chemotherapy (LSG9) for intermediate- or high-grade non-Hodgkin's lymphoma: Japan Clinical Oncology Group Study 9002.
Kinoshita T, Hotta T, Tobinai K, Kobayashi T, Ishizuka N, Tomonaga M, Sai T, Ohno Y, Kasai M, Ogura M, Mikuni C, Toki H, Sano M, Masaki Y, Ohtsu T, Matsuno Y, Takenaka T, Shirakawa S, Shimoyama M; Japan Clinical Oncology Group. Kinoshita T, et al. Among authors: ogura m. Int J Hematol. 2004 Nov;80(4):341-50. doi: 10.1532/ijh97.04085. Int J Hematol. 2004. PMID: 15615259 Clinical Trial.
Phase II study of oral fludarabine phosphate in relapsed indolent B-Cell non-Hodgkin's lymphoma.
Tobinai K, Watanabe T, Ogura M, Morishima Y, Ogawa Y, Ishizawa K, Minami H, Utsunomiya A, Taniwaki M, Terauchi T, Nawano S, Matsusako M, Matsuno Y, Nakamura S, Mori S, Ohashi Y, Hayashi M, Seriu T, Hotta T. Tobinai K, et al. Among authors: ogura m. J Clin Oncol. 2006 Jan 1;24(1):174-80. doi: 10.1200/JCO.2005.03.9313. Epub 2005 Dec 5. J Clin Oncol. 2006. PMID: 16330664 Clinical Trial.
Once-weekly epoetin-beta improves hemoglobin levels in cancer patients with chemotherapy-induced anemia: A randomized, double-blind, dose-finding study.
Morishima Y, Ogura M, Yoneda S, Sakai H, Tobinai K, Nishiwaki Y, Minami H, Hotta T, Ezaki K, Ohe Y, Yokoyama A, Tsuboi M, Mori K, Watanabe K, Ohashi Y, Hirashima K, Saijo N; Japan Erythropoietin Study Group. Morishima Y, et al. Among authors: ogura m. Jpn J Clin Oncol. 2006 Oct;36(10):655-61. doi: 10.1093/jjco/hyl097. Epub 2006 Sep 20. Jpn J Clin Oncol. 2006. PMID: 16987908 Clinical Trial.
Phase II study of chemotherapy and stem cell transplantation for adult acute lymphoblastic leukemia or lymphoblastic lymphoma: Japan Clinical Oncology Group Study 9004.
Tobinai K, Takeyama K, Arima F, Aikawa K, Kobayashi T, Hanada S, Kasai M, Ogura M, Sueoka E, Mukai K, Tajima K, Fukuda H, Shirakawa S, Hotta T, Masanori S; Lymphoma Study Group of the Japan Clinical Oncology Group. Tobinai K, et al. Among authors: ogura m. Cancer Sci. 2007 Sep;98(9):1350-7. doi: 10.1111/j.1349-7006.2007.00556.x. Epub 2007 Jul 19. Cancer Sci. 2007. PMID: 17640299 Free PMC article. Clinical Trial.
Phase I and II pharmacokinetic and pharmacodynamic study of the proteasome inhibitor bortezomib in Japanese patients with relapsed or refractory multiple myeloma.
Ogawa Y, Tobinai K, Ogura M, Ando K, Tsuchiya T, Kobayashi Y, Watanabe T, Maruyama D, Morishima Y, Kagami Y, Taji H, Minami H, Itoh K, Nakata M, Hotta T. Ogawa Y, et al. Among authors: ogura m. Cancer Sci. 2008 Jan;99(1):140-4. doi: 10.1111/j.1349-7006.2007.00638.x. Epub 2007 Oct 27. Cancer Sci. 2008. PMID: 17970782 Free PMC article. Clinical Trial.
Phase III study to evaluate the use of high-dose chemotherapy as consolidation of treatment for high-risk postoperative breast cancer: Japan Clinical Oncology Group study, JCOG 9208.
Tokuda Y, Tajima T, Narabayashi M, Takeyama K, Watanabe T, Fukutomi T, Chou T, Sano M, Igarashi T, Sasaki Y, Ogura M, Miura S, Okamoto S, Ogita M, Kasai M, Kobayashi T, Fukuda H, Takashima S, Tobinai K; Autologous Bone Marrow Transplantation Study Group; Breast Cancer Study Group of the Japan Clinical Oncology Group (JCOG). Tokuda Y, et al. Among authors: ogura m. Cancer Sci. 2008 Jan;99(1):145-51. doi: 10.1111/j.1349-7006.2007.00639.x. Epub 2007 Oct 25. Cancer Sci. 2008. PMID: 17970786 Free PMC article. Clinical Trial.
1,250 results